Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 2Anemia 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Genital Neoplasms, Female 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Paclitaxel 95Carboplatin 77pembrolizumab 74Cisplatin 29Bevacizumab 27Surveys and Questionnaires 23Radiotherapy 22Letrozole 22Doxorubicin 21Megestrol Acetate 20olaparib 19lenvatinib 19Specimen Handling 18Taxes 17Magnetic Resonance Spectroscopy 17Docetaxel 17Nivolumab 16dostarlimab 15Metformin 15Blood Specimen Collection 14Observation 13Gemcitabine 13Biopsy 13durvalumab 12Medroxyprogesterone Acetate 12Trastuzumab 11Indocyanine Green 11Fulvestrant 11temsirolimus 10abemaciclib 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × Darbepoetin alfa × Gynecologic × Clear all
NCT06184867 2026-03-06

CATALYST

Rutgers, The State University of New Jersey

Phase NA Completed
50 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡